ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcrip
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
(ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer October 23, 2026 8:00 AM EDT Dominic Piscitelli - Chief Financial OfficerJacob Chacko - President, CEO & DirectorLori Friedman - Chief Scientific OfficerPratik Multani - Chief Medical OfficerKeith Lui - Senior VP of Commercial & Medical Affairs Joshua SabariPrakhar Agrawal - Cantor Fitzgerald & Co., Research DivisionFarzin Haque - Jefferies LLC, Research DivisionDerek Archila - Wells Fargo Securities, LLC, Research DivisionCharles KirbyAsthika Goonewardene - Leerink Partners LLC, Research DivisionJoohwan Kim - Citigroup Inc., Research DivisionPaul Jeng - Guggenheim Securities, LLC, Research DivisionKristin K.
Welcome to the ORIC Enozertinib Program Update Call.
[Operator Instructions] Please be advised that today's conference is being recorded.
[Operator Instructions] I would now like to hand the conference over to your speaker today, Dominic Piscitelli, CFO.
Dominic PiscitelliChief Financial Officer Good afternoon, and welcome to the ORIC Pharmaceuticals Enozertinib Program Update Conference Call.
Earlier today, we issued a press release highlighting updated data from our ongoing Phase Ib study of enozertinib in first-line non-small cell lung cancer patients with EGFR atypical mutations.
You can find the press release on the Investor page of oricpharma.com.
We have prerecorded our prepared remarks, after which we will host a live Q&A session.
Before we begin, starting on Slide 2, during this conference call, we will be making forward-looking statements, including those based on our current expectations and projections about future events and trends that may affect our business, utilizing data available to us as of the cutoff date set forth on the applicable slide.
ORIC's actual results may differ materially from those expressed in or indicated by such forward-looking statements.
For a description of risk factors associated with investing.
| Product | Price | Change |
|---|---|---|
| Brent Crude | $102.14/bbl | +0.34% |
| WTI Crude | $96.90/bbl | +0.21% |
| EN590 Diesel | $846/MT | +0.18% |
| Jet Fuel A-1 | $1090/MT | +0.55% |
| Mazut M100 | $450/MT | -0.15% |
| Bitumen 60/70 | $470/MT | +0.08% |
| Sulphur Gran 99.5% | $470/MT | -0.44% |
| Urea 46% Gran | $650/MT | +1.12% |
| NPK 16-16-16 | $460/MT | -0.28% |
| Nat Gas TTF | $15.42/MMBtu | +0.92% |
Comments
Post a Comment